Paris-based Generare Raises €20 Million To Scale Microbial Genome-Based Drug Discovery Platform

The round was co-led by Alven and Daphni, with participation from existing investors including Galion.exe, Teampact Ventures, and VIVES Partners.

Founded in 2023 by Dr. Vincent Libis and Guillaume Vandenesch Generare has built a proprietary platform that decodes microbial genomes to uncover hidden chemical compounds and generate new molecular data for drug discovery.

The company is developing a high-quality dataset of previously untapped molecular chemistry, creating a growing library of novel compounds with defined structure, biological activity, and drug development potential.

Read Also - Sensmet Raises €1.5M To Scale Real-time Metals Monitoring Technology In Europe

The new funding will enable Generare to scale its platform significantly, increasing capacity to over 2,000 molecules by 2027 and targeting more than 10,000 in the long term. It will also nearly double its 25-member team of experts across biology, chemistry, and engineering from multiple countries.

The company is also supported by advisors including Dr. Frank Petersen, former Executive Director at Novartis, and Professor Nadine Ziemert, a leading expert in microbial biosynthetic gene clusters.

In just three years, Generare claims to have become a leading platform for producing evolution-based molecular data. The company says that while the industry discovered only a few dozen new molecules in 2025, it identified over 200 itself. These molecules are now being used in research labs to develop new treatments for life-threatening diseases.

Guillaume Vandenesch, CEO and co-founder, Generare, said, ”Drug discovery has a data problem. The entire field trains its models on the same recycled chemistry and expects different outcomes. The bottleneck is not algorithms, it is the absence of genuinely novel, high-quality molecular data and we’re solving that by building the largest proprietary dataset of cryptic small molecules. These molecules, shaped by 3 billion years of evolution and with drug properties no synthetic library can match, will fuel the next century of drug discovery.”

“Nature has been the n°1 source of innovative modes of action for drugs and we’ve only scratched the surface of its potential. We’re building the infrastructure to change that with the largest commercial library of evolution-derived molecules in the world, a dataset that improves with every cycle, and a platform that can supply companies with genuinely new starting points for drug discovery,” said Dr Vincent Libis, CSO and co-founder at Generare.

About Generare

Generare is a Paris-based biotech company decoding microbial genomes to uncover hidden chemistry and generate high-quality molecular data for drug discovery. It is building a large dataset of novel compounds from previously unread biological information. Its platform aims to transform drug development by revealing new molecular insights from life’s evolution.